First Patient Enrolled in GORE® TAG® Thoracic Branch Endoprosthesis Early Feasibility Study
First Early Feasibility Study of a Gore Device Will Assess Treatment of Aortic Arch Aneurysms
GORE® EXCLUDER® Conformable AAA Endoprosthesis Receives Approval for Clinical Study in the US and Japan
Device designed to bring endovascular therapy options to patients previously considered untreatable
GORE® DrySeal Flex Introducer Sheath Advances Care through Access
New sheath provides exceptional access to challenging anatomies and branch vessels
Improved GORE® DrySeal Sheath with Hydrophilic Coating Launches in Europe
New Product Engineered to Increase Sheath Lubricity, Minimize Coating Particulation for Easier Insertion and Removal in Treating Patients with AAA and TAA
Gore Launches Lower Profile GORE® EXCLUDER® AAA Endoprosthesis Contralateral Leg
Components in US and Europe
Gore Achieves 40 Million Implants Sold Worldwide as it Celebrates 40 Years of Performance
Milestones a testament on its 40-year legacy of designing devices to improve patient outcomes
Gore Marks 20th Year on 100 Best Companies to Work For® List
Gore has appeared in every edition of the rankings, published annually in Fortune magazine. The company is among just 12 “Great Place to Work Legends” to hold this distinction.
Gore Announces First-in-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR
New delivery system provides controlled and predictable placement of Gore’s highly conformable and time-tested stent graft
Gore Completes Patient Enrollment in U.S. Pivotal Clinical Study of GORE® CARDIOFORM ASD Occluder
New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure